Eton Pharmaceuticals
Develops and commercializes rare-disease therapies through product launches and rights agreements.
$59.78
After-hours close−0.01 (−0.02%)
At close$59.79(−4.60%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 73.22%20.06M sharesInsiders 5.16%1.41M sharesOther 21.62%5.92M shares
Shares outstanding 27.39M · Float 21.05M · 76.8% free float
Institutions13F, as of Jun 30, 2026
172 holders · 20.06M shares · 58 new positions · 117 increased · 33 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Opaleye Management Inc. | 2.86M | 10.44% | 0 | Aug 14, 2026 |
| Ecor1 Capital, LLC | 2.17M | 7.93% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 1.90M | 6.92% | +178.5K | Aug 7, 2026 |
| Nantahala Capital Management, LLC | 1.18M | 4.29% | 0 | Aug 19, 2026 |
| Vanguard Capital Management LLC | 976.6K | 3.57% | −17.5K | Aug 13, 2026 |
| Morgan Stanley | 768.0K | 2.80% | +290.0K | Aug 13, 2026 |
| State Street Corp | 701.8K | 2.56% | +171.6K | Aug 7, 2026 |
| Geode Capital Management, LLC | 652.3K | 2.38% | +74.6K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| EcoR1 Capital, LLCincl. EcoR1 Capital Fund Qualified, L.P., Oleg Nodelman | 11.00% | 1.40M | 13G | Dec 9, 2024 ↗ |
| BlackRock, Inc. | 5.70% | 1.53M | 13G | Jul 17, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Sean Brynjelsen | director, officer: President & CEO | 961.2K | 3.51% | Aug 20, 2026 |
| James R. Gruber | officer: Chief Financial Officer | 213.4K | 0.78% | Jan 14, 2026 |
| Ipek Erdogan-Trinkaus | officer: Chief Commercial Officer | 80.0K | 0.29% | Aug 4, 2026 |
| Paul V. Maier | director | 59.7K | 0.22% | Aug 28, 2026 |
| Opaleye Management Inc. | 10 percent owner | 40.0K | 0.15% | Jul 16, 2026 |
| David Krempa | officer: Chief Business Officer | 37.0K | 0.14% | Aug 24, 2026 |
| Judith M. Matthews | officer: Chief Financial Officer | 32.2K | 0.12% | Aug 4, 2026 |
| Jennifer McKie Adams | director | 10.0K | 0.04% | Aug 4, 2026 |
| Charles J. Casamento | director | 10.0K | 0.04% | Aug 4, 2026 |
| Norbert G. Riedel | director | 10.0K | 0.04% | Aug 4, 2026 |
2 ten-percent owners hold 2.02M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (33.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 28, 2026 | Paul V. Maierdirector | Sale · 3 lots | 50,000 | $59.07 | 59,745 |
| Aug 24, 2026 | David Krempaofficer: Chief Business Officer | Sale | 25,000 | $65.07 | 37,025 |
| Aug 20, 2026 | Sean Brynjelsendirector, officer: President & CEO | Sale · 3 lots | 91,022 | $60.70 | 961,194 |
| Aug 19, 2026 | Sean Brynjelsendirector, officer: President & CEO | Sale | 8,978 | $62.65 | 1,052,216 |
| Jul 14, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 28,315 | $37.54 | 40,000 |
| Jul 7, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 26,685 | $38.37 | 53,315 |
| Jul 2, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 90,000 | $37.39 | 60,000 |
| Jul 6, 2026 | Opaleye Management Inc.10 percent owner | Sale | 10,000 | $38.00 | 2,700,000 |
| Jun 17, 2026 | Jennifer McKie Adamsdirector | Sale | 50,000 | $32.48 | 0 |
| May 28, 2026 | Sean Brynjelsendirector, officer: President & CEO | Sale · 2 lots | 120,000 | $31.88 | 833,694 |
CongressHouse and Senate disclosures
Not reported.